)
Edge14 Aug 2026
Deutsche Qualität: The Story of Birkenstock
From an 18th-century German shoemaker to a global footwear brand, how Birkenstock turned an orthopedic insole into the world's most popular sandal.
RemeGen
RemeGen (9995) investor relations material
RemeGen Q2 2026 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q2 2026 earnings summary24 Aug, 2026
Executive summary
Revenue surged 435.74% year-over-year to RMB5,850.2 million, driven by strong sales of telitacicept and disitamab vedotin, and a major licensing deal with AbbVie for RC148.
Net profit reached RMB4,662.3 million, reversing a loss of RMB449.6 million in the prior year period.
Significant pipeline progress with multiple regulatory approvals and clinical milestones for telitacicept and disitamab vedotin.
Financial highlights
Gross profit was RMB5,581.3 million for the six months ended June 30, 2026.
Research and development expenses decreased 36% year-over-year to RMB414.1 million.
Selling and distribution expenses rose to RMB549.6 million, and administrative expenses increased to RMB262.4 million.
Cash and cash equivalents stood at RMB1,528.9 million as of June 30, 2026.
Gearing ratio improved to 15.6% from 50.2% at year-end 2025.
Outlook and guidance
Plans to further commercialize telitacicept and disitamab vedotin and expand market presence in China.
Continued acceleration of clinical trials and regulatory filings for pipeline products.
Ongoing international collaborations with Vor Bio, Pfizer/Seagen, Santen China, and AbbVie to advance global clinical programs.
Drivers for the 36% year-on-year R&D cost decline
Reasons for RC28-E DME application withdrawal
Disitamab vedotin 1L gastric cancer efficacy data
Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.Research faster. Power your platform.
Latest events from RemeGen
- Revenue up 76.5% year-over-year, with strong pipeline progress and higher R&D costs.9995
Q2 2024 - Revenue up 59% to RMB1.71B, losses narrowed, and pipeline advanced with key approvals.9995Q4 2024
- Q3 2024 revenue surged 57% year-over-year, but high R&D costs drove continued net losses.9995Q3 2024
- 2025 revenue reached RMB 3,251 million, with profitability and major global licensing deals.9995Q4 2025
- Revenue up 47.6%, net loss narrowed, and major clinical and licensing milestones achieved.9995Q2 2025
- Q1 2025 revenue rose 59% to RMB 525.97M, margins improved, and net loss narrowed.9995Q1 2025
- Revenue up 33%, losses narrowed, and pipeline progress supports positive outlook.9995Q3 2025
- Revenue up 24.76% and net profit reached RMB 328M, reversing last year's loss.9995Q1 2026
Next RemeGen earnings date
Q3 202629 Oct, 2026
RemeGen
Next RemeGen earnings date
Q3 202629 Oct, 2026
The essential earnings season companion
The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
)
)
Frequently asked questions
Explore our global coverage